← Back to Search

Behavioural Intervention

Implementing "Explore Transplant"- A Pilot Study

N/A
Waitlist Available
Led By Istvan Mucsi
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Patients with End Stage Kidney Disease (ESKD) require Renal Replacement Therapy (RRT) in order to survive, be it dialysis or kidney transplantation (KT). Of the two modalities, KT has been associated with better quality of life (QOL) \[1-3\], reduced morbidity and mortality\[4, 5\], and reduced healthcare costs\[6\]. Studies in the US have shown that patients receiving tailored transplant education were more likely to complete the transplant evaluation \[9, 14, 15\]. For instance, patients receiving the Explore Transplant (ET) education program designed by Dr. Waterman, were more knowledgeable about KT and more likely to complete KT evaluation than control patients. Currently, there is a lack of standardized KT education in Ontario. Traditional approaches have been insufficient in providing the necessary education and information to enable patients to make an informed decision about their care. To address this issue, the study will assess the impact of kidney transplant related education using the Explore Transplant Ontario (ETO) education program on kidney transplant-related knowledge and on readiness to consider KT, readiness to consider living donor KT, and wait list/referral rates in patients undergoing maintenance hemodialysis. In order to comprehensively measure this impact, 5 variables will be explored. 1. Readiness to consider DDKT 2. Readiness to consider LDKT 3. KT related knowledge in patients 4. Proportion of patients waitlisted or undergoing KT workup at 6 and 12 months after administration of ETO 5. Proportion of patients who have identified at least one potential living donor at 6 and 12 months after administration of ETO The hypotheses are as follows: 1. Readiness to consider DDKT will be higher in the "intervention" group compared to the "control" group at follow up. 2. Readiness to consider LDKT will be higher in the "intervention" group compared to the "control" group at follow up. 3. The KT related knowledge of the patients will be higher in the "intervention" group compared to the "control" group at follow up. 4. The proportion of patients waitlisted or undergoing KT workup at 6 and 12 month after the KT education will be higher in the "intervention" group compared to the "control" group. 5. The proportion of patients who have at least one potential living donor at 6 and 12 month after the KT education will be higher in the "intervention" group compared to the "control" group.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Explore Transplant OntarioExperimental Treatment1 Intervention
Intervention 'Implementing "Explore Transplant" Education'
Group II: ControlActive Control1 Intervention
The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,095 Total Patients Enrolled
2 Trials studying Kidney Failure
100 Patients Enrolled for Kidney Failure
Istvan MucsiPrincipal InvestigatorToronto General Hospital
1 Previous Clinical Trials
36 Total Patients Enrolled
~25 spots leftby Dec 2025